IP Library Granted Patent US 10,485,833
Granted Patent B2
US 10,485,833 · App. 12/874,636 · Granted Nov 26, 2019

Xanthophyll composition containing macular pigments and a process for its preparation

Inventors: Sunil Kumar T. K. (Angamally South, IN); Sherena P. Abdulkadir (Angamally South, IN)
Assignee: OmniActive Health Technologies Limited
A61K36/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,485,833
App. No.
12/874,636
Granted
Nov 26, 2019
Kind
B2
Abstract

A xanthophyll composition that contains macular pigments including trans-lutein and zeaxanthin isomers, namely, (R,R)-zeaxanthin and (R,S)-zeaxanthin, derived from the plant extract/oleoresin containing xanthophylls/xanthophylls esters which is safe for human consumption and useful for nutrition and health care. The composition has at least 80% by weight that is total xanthophylls, of which the ratio of trans-lutein and zeaxanthin isomers being in the range of about 4:1 to about 6:1 and the ratio of the isomers of zeaxanthin being in the range of about 80 to 20:20 to 80.

Claims (23)

1. A xanthophyll composition consisting of an extract of marigold that includes a mixture of converted xanthophylls and obtained from (1) and (2) below, wherein the mixture of converted xanthophylls includes trans-lutein obtained from (1) and (2) below and zeaxanthin isomers obtained from (1) and (2) below, wherein the zeaxanthin isomers obtained from (1) and (2) below consists of (R,R)-zeaxanthin obtained from (1) and (2) below and lutein that has been chemically converted by (1) and (2) below through saponification and isomerization:

(1) admixing marigold oleoresin obtained by hexane extraction and containing xanthophyll esters with an alkaline solution of 1-propanol, wherein the ratio of alkali and 1-propanol is in the range of 1:0.5 to 1:1 by weight/volume; and

(2) heating the resultant mass at a temperature in the range 70-100 degree C. for a period in the range of 1 to 5 hrs;

wherein the lutein that has been chemically converted by (1) and (2) through saponification and isomerization is not found naturally in marigold;

wherein (1) and (2) result in the mixture of converted xanthophylls;

wherein the xanthophyll composition is safe for human consumption and useful for nutrition and health care, the xanthophyll composition comprising: at least 80% by weight total xanthophylls obtained from (1) and (2), of which at least 80% by weight is trans-lutein obtained from (1) and (2), where the ratio of trans-lutein obtained from (1) and (2) to zeaxanthin isomers obtained from (1) and (2) is in the range of about 4:1 to about 6:1, and the ratio of (R,R)-zeaxanthin obtained from (1) and (2) to the lutein that has been chemically converted by (1) and (2) through saponification and isomerization is in the range of 80:20 to 20:80.

2. The xanthophyll composition as claimed in claim 1 , wherein the composition contains at least 85% by weight of total xanthophylls, of which the trans-lutein content is at least 85%.

3. The xanthophyll composition as claimed in claim 1 , wherein the composition contains at least 85% by weight of total xanthophylls, of which at least 80% by weight being trans-lutein, at least 6% by weight being (R,R)-zeaxanthin and at least 6% by weight being the lutein that has been chemically converted by (1) and (2) through saponification and isomerization.

4. The xanthophyll composition as claimed in claim 1 , wherein the composition contains at least 85% by weight trans-lutein and at least 4% by weight (R,R)-zeaxanthin and at least 5% by weight of the lutein that has been chemically converted by (1) and (2) through saponification and isomerization.

5. The xanthophyll composition as claimed in claim 1 , wherein the composition containing at least 85% by weight of total xanthophylls, of which at least 80% by weight being trans-lutein, the remaining 15% by weight being zeaxanthin isomers, including (R,R)-zeaxanthin and the lutein that has been chemically converted by (1) and (2) through saponification and isomerization.

6. A process for the preparation of a xanthophyll composition containing macular pigments of trans-lutein, zeaxanthin isomers, including (R,R)-zeaxanthin and (R,S)- zeaxanthin, derived from the plant extract/oleoresin containing xanthophylls/xanthophylls esters which is safe for human consumption and useful for nutrition and health care which comprises:

(a) saponifying and partially isomerising simultaneously xanthophyll esters present in a plant extract/oleoresin containing xanthophyll esters by admixing the extract/oleoresin with alkaline solution of 1-propanol, the ratio of alkali and 1-propanol being in the range of 1:0.5 to 1:1 by weight/volume, heating the resultant mass at a temperature in the range 70-100 degree C. for a period in the range of 1 to 5 hrs to obtain a saponified/isomerised crude concentrate;

(b) admixing the resultant saponified/isomerised crude concentrate obtained in step (a) with water, the ratio of the concentrate and water used being in the range from 1:2 to 1:3 volume/volume, to form a diluted oily mixture;

(c) extracting the diluted oily mixture obtained in step (b) with ethyl acetate, the ratio of diluted oily mixture and ethyl acetate used being in the range of 1:1.5 to 1:2 volume/volume to get an extract containing the xanthophyll composition;

(d) evaporating the composition obtained in step (c) to remove ethyl acetate;

(e) purifying the composition resulting from step (d) by washing first with a non-polar solvent and later with a polar solvent and filtering; and

drying the resulting composition under vacuum at a temperature in the range of 40 to 45 degree C. for a period ranging from 48-72 hours.

7. The process as claimed in claim 6 , wherein the plant extract/oleoresin containing xanthophyll esters used is derived from marigold flowers.

8. The process as claimed in claim 6 , wherein the non-polar solvent used in step (e) is selected from pentane, hexane, and heptane, and the polar solvent used is selected from a lower aliphatic alcohol.

9. The process as claimed in claim 6 , further comprising recovering the ethyl acetate used in step (c) for reuse.

10. The process as claimed in claim 6 , further comprising storing the resulting composition in an inert atmosphere at 20 degree C.

11. The process as claimed in claim 6 , wherein the plant extract/oleoresin containing xanthophyll esters is marigold, where the marigold is the single source of material providing the plant extract/oleoresin containing xanthophyll esters.

12. The process as claimed in claim 6 , wherein the non-polar and polar solvents are selected from generally recognized as safe (GRAS) reagents, which are safe for human consumption and suitable for nutrition and health care.

Assignments (3)
CHANGE OF ADDRESS Recorded Oct 21, 2019
From: OMNIACTIVE HEALTH TECHNOLOGIES LIMITED
To: OMNIACTIVE HEALTH TECHNOLOGIES LIMITED
Reel/Frame 050779/0992 →
CHANGE OF NAME Recorded Oct 18, 2019
From: OMNIACTIVE HEALTH TECHNOLOGIES PRIVATE LIMITED
To: OMNIACTIVE HEALTH TECHNOLOGIES LIMITED
Reel/Frame 052507/0786 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2010
From: KUMAR T.K., SUNIL; ABDULKADIR, SHERENA P.
To: OMNIACTIVE HEALTH TECHNOLOGIES PVT LTD.
Reel/Frame 025301/0104 →
Priority Claims (1)
IN 2008/MUM/2009 · Sep 2, 2009 · national
Continuity (2)
Provisional Application 61256667 · Oct 30, 2009
Related Publication 20110065805A1 · Mar 17, 2011
Cited By (1)
US 12,576,043